Aster Capital Management (Difc) LTD Lineage Cell Therapeutics, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $441 Billion
- Q2 2025
A detailed history of Aster Capital Management (Difc) LTD transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 218,241 shares of LCTX stock, worth $371,009. This represents 0.04% of its overall portfolio holdings.
Number of Shares
218,241Holding current value
$371,009% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
142Shares Held
106MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$84.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$16.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$14.4 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$11.5 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$9.17 Million6.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $289M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...